 This study is a Phase I, single dose, dose-escalation study to study the pharmacokinetics, safety, signs of efficacy, receptor occupancy and pharmacodynamics biomarkers sTNFR1 and ST2 of Neihulizumab in patients with steroid-refractory acute GvHD. Up to 24 patients will be recruited in 4-8 clinical centers in US. 